×

Novavax to Present RSV Vaccine Clinical and Preclinical Results at ICAAC

Novavax logo

ROCKVILLE, Md., Sept. 3, 2013 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq:NVAX) a clinical-stage biopharmaceutical company creating novel vaccines based on recombinant nanoparticle technology, today announced that it will present data from recent clinical and preclinical studies of its respiratory syncytial virus F-protein (RSV F) nanoparticle vaccine candidate in poster sessions at the 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Denver Colorado, September 11-13, 2013.

One poster will describe in detail the immunogenicity and safety of Novavax' RSV F nanoparticle vaccine observed in a Phase 1 clinical study of 220 healthy elderly adults (≥60 years of age, mean age of 68 years of age), top-line results of which were reported by Novavax in July. The second poster will present data from a preclinical passive immunization and challenge study which evaluated the protective effects of RSV F nanoparticle vaccine-induced palivizumab-like antibodies in a relevant model, the cotton rat, which was previously predictive for protection in infant passive immunization studies.

The poster presentation numbers, titles, dates and times are listed below:

  • Poster B-501d: "RSV F Protein Vaccine Is Well-Tolerated and Immunogenic in Elders" will present data from the company's recently completed Phase 1 clinical trial of its RSV vaccine candidate in healthy elderly adults. [Exhibit Hall A, Wednesday, September 11 from 11:00am to 1:00 pm]
  • Poster B-501a: "Passive Immunization with RSV F Vaccine-Induced Polyclonal Antibodies Protect Cotton Rats From RSV A Challenge" [Exhibit Hall A, Wednesday, September 11 from 11:00am to 1:00 pm]

About RSV

RSV is a major respiratory pathogen in all humans regardless of age. In healthy adults, RSV infections are generally mild to moderate in severity, but may be more severe in infants and young children as well as the elderly and adults with underlying chronic cardiac or pulmonary disease. It is estimated that between 11,000 to 17,000 adults die of RSV infection annually in the U.S., with up to 180,000 hospitalizations for serious respiratory symptoms. Globally, RSV is a common cause of childhood respiratory infection, with a disease burden of 64 million cases and approximately 160,000 deaths annually. Severe RSV disease results in 3.4 million hospital admissions per year globally and disproportionately affects infants below six months of age. Currently, there is no approved RSV prophylactic vaccine available.

About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage biopharmaceutical company creating novel vaccines to address a broad range of infectious diseases worldwide. Using Innovative proprietary recombinant protein nanoparticle vaccine technology, as well as new and efficient manufacturing approaches, the company produces vaccine candidates to efficiently and effectively respond to both known and newly emergent diseases. Novavax is involved in several international partnerships, including collaborations with Cadila Pharmaceuticals of India, LG Life Sciences of Korea, PATH and recently acquired Isconova AB, a leading vaccine adjuvant company located in Sweden. Together, Novavax' network supports its global commercialization strategy to create real and lasting change in the biopharmaceutical and vaccinology fields. Additional information about Novavax is available on the company's website, novavax.com.

Forward-Looking Statements

Statements herein relating to the future of Novavax and its ongoing development of its recombinant nanoparticle vaccine products are forward-looking statements. Novavax cautions that these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include those identified under the heading "Risk Factors" in the Novavax Annual Report on Form 10-K for the year ended December 31, 2012, and Form 10-Q for the period ended June 30, 2013, both filed with the Securities and Exchange Commission (SEC). Investors are cautioned not to place considerable reliance on forward-looking statements contained in this press release and encouraged to read the Company's filings with the SEC, available at www.sec.gov, for a discussion of these and other risks and uncertainties. The forward-looking statements in this press release speak only as of the date of this document, and Novavax undertakes no obligation to update or revise any of the statements. Novavax' business is subject to substantial risks and uncertainties, including those referenced above and investors, potential investors, and others should give careful consideration to these risks and uncertainties.

CONTACT: Barclay Phillips SVP, Chief Financial Officer and Treasurer Novavax, Inc. 240-268-2000

Source:Novavax, Inc.